Sign In / Register
Recombinant Human FGF-23 Protein Best Seller
Catalog # 2604-FG | R&D Systems, Inc. a Bio-Techne Brand
Key Product Details
Product Specifications
Source
Mouse myeloma cell line, NS0-derived human FGF-23 protein
Tyr25-Ile251 (Arg179Gln), with a C-terminal 6-His tag
Tyr25-Ile251 (Arg179Gln), with a C-terminal 6-His tag
Purity
>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
N-terminal Sequence Analysis
Tyr25
Predicted Molecular Mass
26.1 kDa
SDS-PAGE
29-34 kDa, reducing conditions
Activity
Measured in a cell proliferation assay using BaF3 mouse pro‑B cells transfected with human FGF RIIIc.
The ED50 for this effect is 0.1‑0.4 µg/mL in the presence of Recombinant Mouse Klotho (Catalog # 1819-KL) and heparin.
The ED50 for this effect is 0.1‑0.4 µg/mL in the presence of Recombinant Mouse Klotho (Catalog # 1819-KL) and heparin.
Scientific Data Images for Recombinant Human FGF-23 Protein
Formulation, Preparation and Storage
Carrier Free
What does CF mean?CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
What formulation is right for me?In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
Carrier: 2604-FG
| Formulation | Lyophilized from a 0.2 μm filtered solution in MOPS, Na2SO4, EDTA and DTT with BSA as a carrier protein. |
| Reconstitution | Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin. |
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Carrier Free: 2604-FG/CF
| Formulation | Lyophilized from a 0.2 μm filtered solution in MOPS, Na2SO4, EDTA and DTT. |
| Reconstitution | Reconstitute at 100 μg/mL in sterile PBS. |
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: FGF-23
Fibroblast growth factor 23 (FGF‑23) is a 30‑32 kDa member of the FGF family, within a subfamily that also includes FGF‑19 and FGF‑21. FGF proteins contain a 120 amino acid (aa) core FGF domain that exhibits a beta‑trefoil structure (1, 2). FGF‑19 subfamily members are highly diffusible molecules owing to their poor ECM/heparin sulfate binding and plasma‑stabilizing intramolecular folds (2‑4). Mature human FGF‑23 contains an atypical (very low affinity) heparin binding site (aa 134‑162), a proteolytic cleavage site (Arg179‑Ser180), and multiple O‑linked glycosylation sites with Thr178 being of particular importance (4‑7). O‑linked glycosylation at Thr178 blocks the cleavage of FGF‑23, thereby preventing loss of FGF‑23 activity (7, 8). Mature human FGF‑23 shows 72% aa identity to mouse FGF‑23 and is active on mouse cells (6). FGF‑23 exerts its effects through a ternary complex that includes Klotho and an FGF receptor (FGF R4 or the "c" isoforms of FGF R1 or FGF R3). Klotho has a restricted distribution that limits FGF‑23 activity (9‑11). FGF‑23 is produced by osteocytes and osteoblasts in response to high circulating phosphate levels, elevated parathyroid hormone, and circulatory volume loading. It functions as an endocrine phosphatonin by suppressing circulating phosphate levels (12). FGF‑23 interaction with renal proximal tubular epithelium decreases the renal resorption of phosphate by down‑regulating phosphate transporters and by suppressing vitamin D production. It also decreases the intestinal absorption of phosphate (13).
References
- Mohammadi, M. et al. (2005) Cytokine Growth Factor Rev. 16:107.
- Fukumoto, S. (2007) Endocr. J. Sep 14; [Epub ahead of print].
- Goetz, R. et al. (2007) Mol. Cell. Biol. 27:3417.
- Harmer, N.J. et al. (2004) Biochemistry 43:629.
- Yamashita, T. et al. (2000) Biochem. Biophys. Res. Commun. 277:494.
- Shimada, T. et al. (2001) Proc. Natl. Acad. Sci. USA 98:6500.
- Frishberg, Y. et al. (2007) J. Bone Miner. Res. 22:235.
- Kato, K. et al. (2006) J. Biol. Chem. 281:18370.
- Zhang, X. et al. (2006) J. Biol. Chem. 281:15694.
- Urakawa, I. et al. (2006) Nature 444:770.
- Kurosu, H. et al. (2006) J. Biol. Chem. 281:6120.
- Razzaque, M.S. and B. Lanske (2007) J. Endocrinol. 194:1.
- Kurosu, H. et. al. (2007) J. Biol. Chem. 282:26687.
Long Name
Fibroblast Growth Factor 23
Alternate Names
FGF23
Gene Symbol
FGF23
UniProt
Product Documents for Recombinant Human FGF-23 Protein
Product Specific Notices for Recombinant Human FGF-23 Protein
For research use only
Citations for Recombinant Human FGF-23 Protein (16)
Showing
1
-
10 of
16 publications
Showing All
Filter By:
Search Title:
Citations are publications that use Bio-Techne products. Selected citations for Recombinant Human FGF-23 Protein include:
-
Species: Human
Sample Types: Whole Cells
Applications: BioassayWB Sneddon et al. (2023-03-07), Mutations in an unrecognized internal NPT2A PDZ motif disrupt phosphate transport causing congenital hypophosphatemia bioRxiv : the preprint server for biology, 2023-00(0).
PMID: 36945373 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayPA Friedman et al. (2022-03-17), RGS14 regulates hormone-sensitive NPT2A-mediated renal phosphate uptake via binding to the NHERF1 scaffolding protein The Journal of Biological Chemistry, 2022-00(0):101836.
PMID: 35307350 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayJ Heil et al. (2021-11-29), Bone marrow sinusoidal endothelium controls terminal erythroid differentiation and reticulocyte maturation Nature Communications, 2021-112(1):6963.
PMID: 34845225 -
Species: Rat
Sample Types: Whole Cells
Applications: Cell CultureX Zhong et al. (2020-01-31), Structure-function relationships of the soluble form of the antiaging protein Klotho have therapeutic implications for managing kidney disease J. Biol. Chem., 2020-00(0).
PMID: 32005658 -
Species: Rat
Sample Types: Whole Cells
Applications: BioassayI Böckmann et al. (2019-09-18), FGF23-Mediated Activation of Local RAAS Promotes Cardiac Hypertrophy and Fibrosis Int J Mol Sci, 2019-020(18).
PMID: 31540546 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayM Rodrat et al. (2018-01-06), Prolonged exposure to 1,25(OH)2D3 and high ionized calcium induces FGF-23 production in intestinal epithelium-like Caco-2 monolayer: A local negative feedback for preventing excessive calcium transport Arch. Biochem. Biophys., 2018-0640(0):10-16.
PMID: 29317227 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayK Yang et al. (2017-06-08), Fibroblast growth factor 23 weakens chemotaxis of human blood neutrophils in microfluidic devices Sci Rep, 2017-07(1):3100.
PMID: 28596573 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayCP Chung et al. (2017-05-02), ?-Klotho expression determines nitric oxide synthesis in response to FGF-23 in human aortic endothelial cells PLoS ONE, 2017-012(5):e0176817.
PMID: 28463984 -
Species: Human
Sample Types: Whole Cells
Applications: Bioassay(2016-07-18), Convergent Signaling Pathways Regulate Parathyroid Hormone and Fibroblast Growth Factor-23 Action on NPT2A-mediated Phosphate Transport J Biol Chem, 2016-00(0).
PMID: 27432882 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayK van der Me et al. (2016-03-25), Regulation of CYP27B1 mRNA Expression in Primary Human Osteoblasts Calcif Tissue Int, 2016-00(0).
PMID: 27016371 -
Species: Human
Sample Types: Whole Cells
Applications: BioassaySix I et al. (2014-04-02), Direct, acute effects of Klotho and FGF23 on vascular smooth muscle and endothelium. PLoS ONE, 2014-09(4):e93423.
PMID: 24695641 -
Species: Mouse
Sample Types: In Vivo,Whole Cells
Applications: Bioassay,In VivoCoe et al. (2014-02-07), FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis. J Biol Chem, 2014-0289(14):9795-810.
PMID: 24509850 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayKharitonenkov et al. (2013-03-11), Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS ONE, 2013-08(3):e58575.
PMID: 23536797 -
Species: Rat
Sample Types: Whole Cells
Applications: BioassayWu et al. (2013-02-22), Antibody-mediated activation of FGFR1 induces FGF23 production and hypophosphatemia. PLoS ONE, 2013-08(2):e57322.
PMID: 23451204 -
Species: Human
Sample Types: Whole Cells
Applications: BioassaySmith R (2012-11-26), Circulating alphaKlotho influences phosphate handling by controlling FGF23 production. J. Clin. Invest., 2012-1122(12):4710-5.
PMID: 23187128 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayTomlinson DC et al. (2010-10-01), Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer. Am. J. Pathol., 2010-1177(5):2379-86.
PMID: 20889570
There are no citations that match your criteria.
Loading...
